Published in N Engl J Med on December 22, 2008
French Registry of Acute Coronary Syndrome (Fast-MI) | NCT00673036
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO) | NCT00995514
Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort (INDUCE-it) | NCT01330589
Stent For Life Observatory (SFL) | NCT01251198
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial (PPD) | NCT01103843
French Cohort of Myocardial Infarction Evaluation (FRENCHIE) | NCT04050956
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke | NCT04072705
Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects (CARES1) | NCT04580602
Pharmacogenomics and Effective Treatment With Clopidogrel | NCT01611545
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009) 6.21
Purinergic signaling during inflammation. N Engl J Med (2012) 4.08
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med (2010) 2.90
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ (2012) 2.88
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy (2012) 2.49
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res (2010) 2.06
Drug interactions--principles, examples and clinical consequences. Dtsch Arztebl Int (2012) 2.02
Personalized medicine: hope or hype? Eur Heart J (2012) 1.80
Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther (2011) 1.69
Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov (2010) 1.66
Gene-by-environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthma. Clin Exp Allergy (2012) 1.50
Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol (2012) 1.44
Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One (2009) 1.43
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010. Heart (2012) 1.31
Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circ Res (2011) 1.31
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J (2009) 1.27
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics (2012) 1.25
Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet (2014) 1.19
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Helicobacter pylori and gastroduodenal ulcer disease. Dtsch Arztebl Int (2009) 1.07
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol (2012) 1.05
Mapping genes that predict treatment outcome in admixed populations. Pharmacogenomics J (2010) 1.05
CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet (2011) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Platelet aggregation pathway. Pharmacogenet Genomics (2011) 1.04
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
The genetics of ischaemic stroke. J Intern Med (2010) 1.01
Clopidogrel pathway. Pharmacogenet Genomics (2010) 0.99
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol (2010) 0.98
Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol (2009) 0.98
A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.97
Significant increase in clopidogrel use across U.S. children's hospitals. Pediatr Cardiol (2010) 0.97
Clopidogrel, genetics, and drug responsiveness. N Engl J Med (2009) 0.97
Cardiovascular risk. Br J Clin Pharmacol (2012) 0.97
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol (2012) 0.97
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev (2009) 0.95
Clinical importance of aspirin and clopidogrel resistance. World J Cardiol (2010) 0.95
Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol (2009) 0.94
The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost (2013) 0.94
Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci (2010) 0.94
Newer agents in antiplatelet therapy: a review. J Blood Med (2012) 0.94
Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries. Trials (2012) 0.94
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet (2015) 0.93
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost (2011) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open (2014) 0.92
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One (2012) 0.91
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost (2011) 0.90
Personalized approaches to clopidogrel therapy: are we there yet? Stroke (2010) 0.90
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Prasugrel. Nat Rev Drug Discov (2009) 0.90
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol (2010) 0.90
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag (2015) 0.90
Genetics of platelet inhibitor treatment. Br J Clin Pharmacol (2014) 0.89
Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol (2010) 0.89
Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Adv Hematol (2010) 0.89
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag (2012) 0.88
Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health (2011) 0.88
Stent thrombosis: incidence, predictors and new technologies. Thrombosis (2012) 0.87
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol (2011) 0.87
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res (2012) 0.86
The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009) 0.86
Medical DNA sequencing. Curr Opin Cardiol (2011) 0.86
Clopidogrel and proton pump inhibitors--where do we stand in 2012? World J Gastroenterol (2012) 0.85
Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol (2010) 0.85
Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention. Heart Vessels (2012) 0.85
Antiplatelet resistance in stroke. Expert Rev Neurother (2011) 0.85
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. Heart Vessels (2011) 0.85
Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej (2015) 0.84
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol (2012) 0.84
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J (2011) 0.84
Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci (2013) 0.84
Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem (2012) 0.84
The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One (2014) 0.84
New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol (2010) 0.84
Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics. PLoS Curr (2010) 0.84
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 14.12
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA (2002) 4.48
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation (2009) 3.98
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 2.78
Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (2008) 2.74
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med (2010) 2.52
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation (2003) 2.26
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest (2004) 2.19
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation (2011) 2.17
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09
Outcomes of myocardial infarction in hospitals with percutaneous coronary intervention facilities. Arch Intern Med (2007) 2.07
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol (2004) 2.04
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J (2012) 1.95
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol (2003) 1.93
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation (2012) 1.84
Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther (2007) 1.83
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J (2009) 1.80
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Ozone air pollution is associated with acute myocardial infarction. Circulation (2005) 1.71
Environmental factors associated with body mass index in a population of Southern France. Eur J Cardiovasc Prev Rehabil (2004) 1.70
The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med (2013) 1.70
Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab (2010) 1.68
Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J (2012) 1.66
MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest (2002) 1.64
Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol (2006) 1.63
Household income is associated with the risk of metabolic syndrome in a sex-specific manner. Diabetes Care (2005) 1.59
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther (2002) 1.57
Fish consumption is associated with lower heart rates. Circulation (2003) 1.56
Independent contribution of dairy products and calcium intake to blood pressure variations at a population level. J Hypertens (2006) 1.56
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol (2003) 1.54
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA (2012) 1.48
Association between the metabolic syndrome and parental history of premature cardiovascular disease. Eur Heart J (2006) 1.47
Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv (2012) 1.47
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47
Relationship between C reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness. J Hypertens (2004) 1.46
Performance assessment of a chest pain unit: Preliminary 2-year experience in the European Georges Pompidou Hospital. Arch Cardiovasc Dis (2009) 1.45
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J (2006) 1.45
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic Clin Pharmacol Toxicol (2011) 1.42
Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation. Transplantation (2008) 1.41
Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients). Am J Cardiol (2011) 1.41
Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers. J Nucl Cardiol (2003) 1.41
Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. Europace (2013) 1.41
Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet (2007) 1.40